Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
International Business Machines Corp. Stock Climbs 4.0%, Outperforms Peers

International Business Machines Corp. Stock Climbs 4.0%, Outperforms Peers

Dow JonesDow Jones2026/09/11 20:35

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of International Business Machines Corp. advanced 4.0% to $243.29 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.9% to 7,656.98 and the Dow Jones Industrial Average rising 1.0% to 52,573.29.

International Business Machines Corp. closed 26.8% below its 52-week high of $332.46, which the company achieved on June 2nd.

The stock outperformed some of its peers, as Microsoft Corp. rose 0.6% to $495.63, Alphabet Inc. Cl C rose 1.5% to $335.45, and Alphabet Inc. Cl A rose 1.77% to $338.50.

Trading volume totaled 4.9 million, compared to the 50-day average of 8.9 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

September 11, 2026 16:35 ET (20:35 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas